adalimumab vs golimumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Crohn's Diseasemonoclonal antibody (fully human IgG1)
Partial signal

NCT00055497 · Phase 3 · completed

Design meets top-tier criteria (randomized, quadruple-blind, placebo-controlled, hard clinical endpoint), but the randomized comparison population was very small (only 55 total randomized participants across 3 arms) and the two primary analysis methods gave discordant significance results (NRI missed, LOCF met), which per the definitions caps this at moderate under both the underpowered-n and mixed/unclear-primary-result tests.

Next expected readout: June 2027 · NCT06045754 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) (met)

Result source: NCT02499783

golimumab · Simponi

Marketed by Johnson & Johnson

Phase 2 in Crohn's Diseasemonoclonal antibody (fully human IgG1)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabgolimumab
Clinical remission (induction)37.3% vs 6.8%+30.5 vs placebo160/80 mg · wk 4 · n 102NCT02499783
1 other result
  • 46.9% vs 27.7% wk 12 · n 64 · Phase 3 · secondary NCT00348283
—Not reported
Endoscopic response (induction)—Trial running · NCT05040464—Not reported
Clinical remission (maintenance)47.4% vs 33.3%+14.1 vs placebo40 mg every other week · wk 56 · n 19NCT00055497
11 other results
  • 66.7% vs 33.3% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 78.9% vs 44.4% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 83.3% vs 44.4% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 38.1% vs 9.1% 40 mg Eow · wk 52 · n 21 · Phase 2/3 · primary NCT00445432
  • 36.3% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 40.2% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 32.8% vs 9.2% wk 52 · n 64 · Phase 3 · secondary NCT00348283
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
—Not reported
Endoscopic response (maintenance)—Trial running · NCT05040464—Not reported

Clinical remission (induction)

adalimumab
37.3% vs 6.8%+30.5 vs placebo160/80 mg · wk 4 · n 102NCT02499783
1 other result
  • 46.9% vs 27.7% wk 12 · n 64 · Phase 3 · secondary NCT00348283
golimumab
—Not reported

Endoscopic response (induction)

adalimumab
—Trial running · NCT05040464
golimumab
—Not reported

Clinical remission (maintenance)

adalimumab
47.4% vs 33.3%+14.1 vs placebo40 mg every other week · wk 56 · n 19NCT00055497
11 other results
  • 66.7% vs 33.3% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 78.9% vs 44.4% 40 mg every other week · wk 56 · n 19 · Phase 3 · primary NCT00055497
  • 83.3% vs 44.4% 40 mg every week · wk 56 · n 18 · Phase 3 · primary NCT00055497
  • 38.1% vs 9.1% 40 mg Eow · wk 52 · n 21 · Phase 2/3 · primary NCT00445432
  • 36.3% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 40.2% vs 38.9% 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00055497
  • 32.8% vs 9.2% wk 52 · n 64 · Phase 3 · secondary NCT00348283
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
  • 57.9% vs 38.9% 40 mg every other week · wk 24 · n 19 · Phase 3 · secondary NCT00055497
  • 94.4% vs 38.9% 40 mg every week · wk 24 · n 18 · Phase 3 · secondary NCT00055497
golimumab
—Not reported

Endoscopic response (maintenance)

adalimumab
—Trial running · NCT05040464
golimumab
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

golimumab: registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab: 4 of 4 rows · golimumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Dropout rate
—40 mg every other weeka
NCT00055497 · Phase 3
show 34 more results
15.8%40 mg every other week
NCT00055497 · Phase 3
11.1%40 mg every week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
40.7%40 mg
NCT00055497 · Phase 3
—160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
48.5%
NCT00195715 · Phase 3
16.9%40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4.4%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
6.8%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
6.8%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
21.4%
NCT02185014 · Phase 3 · monotherapy
61%
NCT00686374 · Phase 3 · monotherapy
—40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
60%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
34.4%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
3%160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
5.9%80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
35.7%80 mg
NCT01958827 · Phase 3 · monotherapy
16.4%40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
36%
NCT02148718 · Phase 4 · registry result, not featured evidence
26.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
26.7%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—40 mg every other weeka
NCT00055497 · Phase 3
show 34 more results
5.3%40 mg every other week
NCT00055497 · Phase 3
5.6%40 mg every week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
12.7%40 mg
NCT00055497 · Phase 3
—160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
15.7%
NCT00195715 · Phase 3
6%40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
1.5%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
3.9%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
2.4%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
7.1%
NCT02185014 · Phase 3 · monotherapy
8%
NCT00686374 · Phase 3 · monotherapy
—40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
—20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
21.9%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
3%160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
5.9%80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
10.7%80 mg
NCT01958827 · Phase 3 · monotherapy
10.9%40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
—
NCT02148718 · Phase 4 · registry result, not featured evidence
20%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
20%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
Serious AEs
5.3%40 mg every other weeka
NCT00055497 · Phase 3
show 34 more results
—40 mg every other week
NCT00055497 · Phase 3
—40 mg every week
NCT00055497 · Phase 3
0%40 mg every week
NCT00055497 · Phase 3
16.7%40 mg
NCT00055497 · Phase 3
2%160/80 mg
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
38.1%
NCT00195715 · Phase 3
—40 mg every other week or every week
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
14.8%
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
4.5%Induction: Higher Induction Dose
NCT02065570 · Phase 3 · monotherapy
4.9%Induction: Standard Induction Dose
NCT02065570 · Phase 3 · monotherapy
4.6%Maintenance: Clinically Adjusted (
NCT02065570 · Phase 3 · monotherapy
6.4%Maintenance: Therapeutic Drug Mana
NCT02065570 · Phase 3 · monotherapy
—Maintenance: Therapeutic Drug Moni
NCT02065570 · Phase 3 · monotherapy
10.7%
NCT02185014 · Phase 3 · monotherapy
48%
NCT00686374 · Phase 3 · monotherapy
23.7%40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
20%20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
8%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
40.6%40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—160 mg/80 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80/40 mg + 40/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
—80 mg/40 mg
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
28.6%80 mg
NCT01958827 · Phase 3 · monotherapy
—40 mg every other week
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
2.3%
NCT02148718 · Phase 4 · registry result, not featured evidence
—Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
6.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
7.7%Low Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
—Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
6.7%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
14.3%Standard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
40 mg every other weeka
nasopharyngitis 26.3% (placebo 38.9%)
crohn's disease aggravated 21.1% (placebo 27.8%)
sinusitis 21.1% (placebo 5.6%)
NCT00055497 · Phase 3
show 28 more results
40 mg every week
crohn's disease aggravated 11.1% (placebo 27.8%)
dizziness (excl vertigo) 11.1% (placebo 5.6%)
nasopharyngitis 11.1% (placebo 38.9%)
NCT00055497 · Phase 3
40 mg
crohn's disease aggravated 17.6% (placebo 27.8%)
nasopharyngitis 16.7% (placebo 38.9%)
headache 14% (placebo 11.1%)
NCT00055497 · Phase 3
160/80 mg
white blood cell count decreased 5.9% (placebo 1%)
cough 4.9% (placebo 0%)
dizziness 3.9% (placebo 0%)
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 39.8%
nasopharyngitis 26.1%
arthralgia 24.7%
NCT00195715 · Phase 3
40 mg every other week or every week
headache 18.9%
nasopharyngitis 14.4%
arthralgia 7.6%
NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3
crohn's disease 23.4% (placebo 29.2%)
headache 14.1% (placebo 9.2%)
nasopharyngitis 14.1% (placebo 12.3%)
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3
nasopharyngitis 6.2%
headache 5.5%
crohn's disease 4.5%
NCT02065570 · Phase 3 · monotherapy
headache 8.7%
arthralgia 7.8%
nausea 7.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 14.7%
nasopharyngitis 13.8%
headache 8.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 13.8%
nasopharyngitis 9.2%
headache 7.3%
NCT02065570 · Phase 3 · monotherapy
crohn's disease 11.9%
arthralgia 7.1%
nausea 6%
NCT02185014 · Phase 3 · monotherapy
viral upper respiratory tract infection 39%
headache 37%
upper respiratory tract infection 31%
NCT00686374 · Phase 3 · monotherapy
40 mg or 20 mg every other week
headache 17.2%
crohn's disease 11.8%
nausea 10.8%
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
20 mg or 10 mg every other week
headache 21.1%
crohn's disease 15.8%
nasopharyngitis 11.6%
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
40 mg Eow
nasopharyngitis 56% (placebo 12%)
rhinorrhoea 16% (placebo 0%)
adverse drug reaction 12% (placebo 4%)
NCT00445432 · Phase 2/3 · monotherapy
40 mg Eow
nasopharyngitis 71.9% (placebo 12%)
adverse drug reaction 18.8% (placebo 4%)
iron deficiency anaemia 18.8% (placebo 0%)
NCT00445432 · Phase 2/3 · monotherapy
160 mg/80 mg + 40/40 mg
adverse drug reaction 11.1% (placebo 4.3%)
application site swelling 11.1% (placebo 0%)
blood creatine phosphokinase (at investigator's discretion) 11.1% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
160 mg/80 mg
headache 9.1% (placebo 4.3%)
upper respiratory tract infection 9.1% (placebo 4.3%)
abdominal distension 6.1% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80/40 mg + 40/40 mg
headache 16.7% (placebo 4.3%)
abdominal distension 8.3% (placebo 0%)
abdominal pain 8.3% (placebo 4.3%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80 mg/40 mg
injection site reaction 8.8% (placebo 8.7%)
malaise 8.8% (placebo 0%)
rhinorrhoea 8.8% (placebo 0%)
NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3
80 mg
nasopharyngitis 46.4%
rash 14.3%
headache 10.7%
NCT01958827 · Phase 3 · monotherapy
40 mg every other week
crohn's disease 16.1%
abdominal pain 7.6%
injection site reaction 7.6%
NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3
300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
arthralgia 18.2%
crohn's disease 16.4%
nasopharyngitis 10.9%
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
vomiting 7%
abdominal mass 5.8%
arthralgia 4.7%
NCT02148718 · Phase 4 · registry result, not featured evidence
Low Induction Dose
leukopenia 20%
pyrexia 13.3%
arthralgia 6.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Low Induction Dose
leukopenia 15.4%
animal bite 7.7%
aphthous stomatitis 7.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Standard Induction Dose
alanine aminotransferase increased 13.3%
aspartate aminotransferase increased 13.3%
abdominal pain 6.7%
NCT02015793 · Phase 2 · registry result, not featured evidence
Standard Induction Dose
mycobacterium tuberculosis complex test positive 14.3%
aspartate aminotransferase increased 7.1%
asthenia 7.1%
NCT02015793 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 24 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Clinical Remission 57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
show 11 more results
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
36.3% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 74 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
66.7% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 12 Participants as posted
78.9% (n=19) vs 44.4% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 15 Participants as posted
83.3% (n=18) vs 44.4% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 15 Participants as posted
57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
40.2% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 82 Participants as posted
38.1% (n=21) vs 9.1% (n=22) placebo @ 52wk*40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy · converted to % from 8 Participants as posted
32.8% (n=64) vs 9.2% (n=65) placebo @ 52wk*
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 21 Subjects as posted
Clinical Remission 14.3% (n=28) @ 4wk80 mg
responder rate · % of participants
No placebo or comparator arm
NCT01958827 · Phase 3 · monotherapy
show 80 more results
25% (n=28) @ 8wk80 mg
NCT01958827 · Phase 3 · monotherapy
28.6% (n=28) @ 12wk80 mg
NCT01958827 · Phase 3 · monotherapy
32.1% (n=28) @ 16wk80 mg
NCT01958827 · Phase 3 · monotherapy
35.7% (n=28) @ 20wk80 mg
NCT01958827 · Phase 3 · monotherapy
42.9% (n=28) @ 24wk80 mg
NCT01958827 · Phase 3 · monotherapy
35.7% (n=28) @ 28wk80 mg
NCT01958827 · Phase 3 · monotherapy
42.9% (n=28) @ 32wk80 mg
NCT01958827 · Phase 3 · monotherapy
39.3% (n=28) @ 36wk80 mg
NCT01958827 · Phase 3 · monotherapy
39.3% (n=28) @ 40wk80 mg
NCT01958827 · Phase 3 · monotherapy
42.9% (n=28) @ 44wk80 mg
NCT01958827 · Phase 3 · monotherapy
39.3% (n=28) @ 48wk80 mg
NCT01958827 · Phase 3 · monotherapy
35.7% (n=28) @ 52wk80 mg
NCT01958827 · Phase 3 · monotherapy
36.3% (n=204) @ 56wk*40 mg
NCT00055497 · Phase 3 · converted to % from 74 Participants as posted
45.6% (n=204) @ 56wk*40 mg
NCT00055497 · Phase 3 · converted to % from 93 Participants as posted
38.7% (n=93) @ 26wk40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
33.3% (n=93) @ 52wk40 mg or 20 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
28.4% (n=95) @ 26wk20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
23.2% (n=95) @ 52wk20 mg or 10 mg every other week
NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3
60% (n=55) @ 10wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
54.5% (n=55) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
59.4% (n=609) @ 48wk
NCT00195715 · Phase 3
68.8% (n=462) @ 108wk
NCT00195715 · Phase 3
69.5% (n=272) @ 156wk
NCT00195715 · Phase 3
46.7% (n=15) @ 204wk
NCT00195715 · Phase 3
43.7% (n=206) @ 4wk
NCT02065570 · Phase 3 · monotherapy
43.5% (n=308) @ 4wk
NCT02065570 · Phase 3 · monotherapy
51.5% (n=206) @ 12wk
NCT02065570 · Phase 3 · monotherapy
62.3% (n=308) @ 12wk
NCT02065570 · Phase 3 · monotherapy
89.2% (n=65) @ 0wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 58 Participants as posted
84.6% (n=65) @ 4wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 55 Participants as posted
89.2% (n=65) @ 8wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 58 Participants as posted
81.5% (n=65) @ 12wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 53 Participants as posted
83.1% (n=65) @ 24wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 54 Participants as posted
80% (n=65) @ 36wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 52 Participants as posted
73.8% (n=65) @ 48wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 48 Participants as posted
75.4% (n=65) @ 60wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 49 Participants as posted
72.3% (n=65) @ 72wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 47 Participants as posted
70.8% (n=65) @ 84wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 46 Participants as posted
69.2% (n=65) @ 96wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 45 Participants as posted
69.2% (n=65) @ 108wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 45 Participants as posted
64.6% (n=65) @ 120wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 42 Participants as posted
61.5% (n=65) @ 144wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 40 Participants as posted
53.8% (n=65) @ 168wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 35 Participants as posted
47.7% (n=65) @ 192wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 31 Participants as posted
41.5% (n=65) @ 216wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 27 Participants as posted
40% (n=65) @ 240wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 26 Participants as posted
35.4% (n=65) @ 264wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 23 Participants as posted
26.2% (n=65) @ 288wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 17 Participants as posted
23.1% (n=65) @ 312wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 15 Participants as posted
12.3% (n=65) @ 336wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 8 Participants as posted
10.8% (n=65) @ 360wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
1.5% (n=65) @ 384wk*
NCT00686374 · Phase 3 · monotherapy · converted to % from 1 Participants as posted
54.65% (n=86) @ 2wk
NCT02148718 · Phase 4 · registry result, not featured evidence
62.79% (n=86) @ 4wk
NCT02148718 · Phase 4 · registry result, not featured evidence
26.7% (n=15) @ 2wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
46.7% (n=15) @ 2wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
40% (n=15) @ 4wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 4wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 6wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 6wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 8wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 8wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 10wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 10wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 12wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 12wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 14wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 14wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 16wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 16wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
60% (n=15) @ 18wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
73.3% (n=15) @ 18wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 20wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 20wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 22wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 22wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 24wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 24wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 26wkLow Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
66.7% (n=15) @ 26wkStandard Induction Dose
NCT02015793 · Phase 2 · registry result, not featured evidence
CR-100 57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
show 11 more results
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
53.9% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
49.5% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 101 Participants as posted
57.9% (n=19) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 11 Participants as posted
94.4% (n=18) vs 38.9% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
53.9% (n=204) vs 38.9% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
49.5% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 101 Participants as posted
CR-70 68.4% (n=19) vs 44.4% (n=18) placebo @ 24wk40 mg every other week
responder rate · % of participants
Maintenance
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
show 11 more results
94.4% (n=18) vs 44.4% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
60.3% (n=204) vs 44.4% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 123 Participants as posted
47.4% (n=19) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 9 Participants as posted
72.2% (n=18) vs 33.3% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 13 Participants as posted
53.9% (n=204) vs 33.3% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 110 Participants as posted
94.7% (n=19) vs 83.3% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 18 Participants as posted
94.4% (n=18) vs 83.3% (n=18) placebo @ 24wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 17 Participants as posted
70.6% (n=204) vs 83.3% (n=18) placebo @ 24wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 144 Participants as posted
78.9% (n=19) vs 72.2% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 15 Participants as posted
88.9% (n=18) vs 72.2% (n=18) placebo @ 56wk*40 mg every week
NCT00055497 · Phase 3 · converted to % from 16 Participants as posted
72.1% (n=204) vs 72.2% (n=18) placebo @ 56wk*40 mg every other week
NCT00055497 · Phase 3 · converted to % from 147 Participants as posted
IBDQ 43.4 vs 29.9 placebo score @ 24wk40 mg every other week
absolute change · score
Maintenance
NCT00055497 · Phase 3
show 6 more results
51.9 vs 29.9 placebo score @ 24wk40 mg every week
NCT00055497 · Phase 3
33.9 vs 29.9 placebo score @ 24wk40 mg every other week
NCT00055497 · Phase 3
45.7 vs 24.7 placebo score @ 56wk40 mg every other week
NCT00055497 · Phase 3
45.2 vs 24.7 placebo score @ 56wk40 mg every week
NCT00055497 · Phase 3
36 vs 24.7 placebo score @ 56wk40 mg every other week
NCT00055497 · Phase 3
27.8 vs 1.8 placebo score @ 52wk40 mg Eow
NCT00445432 · Phase 2/3 · monotherapy
Clinical Remission 37.3% (n=102) vs 6.8% (n=103) placebo @ 4wk160/80 mg
responder rate · % of participants
Induction
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
show 1 more result
46.9% (n=64) vs 27.7% (n=65) placebo @ 12wk*
NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 · converted to % from 30 Subjects as posted
CDAI 67.6% (n=102) vs 27.2% (n=103) placebo @ 4wk160/80 mg
responder rate · % of participants
Induction
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
IBDQ Remission 40.2% (n=102) vs 20.4% (n=103) placebo @ 4wk160/80 mg
responder rate · % of participants
Induction
NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3
Clinical Response 100 85.7% (n=272) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Clinical Response 70 91.2% (n=272) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3
Corticosteroid-free Clinical Remission 50% (n=16) @ 10wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
responder rate · % of participants
No placebo or comparator arm
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
56.3% (n=16) @ 26wk300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral)
NCT02764762 · Phase 4 · registry result, not featured evidence · combination
63.1% (n=103) @ 156wk
NCT00195715 · Phase 3
48% (n=100) @ 12wk
NCT02065570 · Phase 3 · monotherapy
52.9% (n=155) @ 12wk
NCT02065570 · Phase 3 · monotherapy
Steroid-free Clinical Response 100 74.8% (n=103) @ 156wk
responder rate · % of participants
No placebo or comparator arm
NCT00195715 · Phase 3

+ 62 further endpoints in the CSV export.

Ulcerative Colitis

Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Ulcerative Colitismonoclonal antibody (fully human IgG1)
Partial signal

NCT00385736 · Phase 3 · completed

Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.

Next expected readout: September 2027 · NCT06257875 (registry estimate)

Reported efficacy

Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)

Result source: NCT00408629

golimumab · Simponi

Marketed by Johnson & Johnson

Approved in Ulcerative Colitismonoclonal antibody (fully human IgG1)
Reliable signal

NCT01863771 · Phase 3 · completed

Design meets the 'strong' bar: randomized, double-blind (participant and investigator masked), placebo-controlled, phase 3, with a hard clinical endpoint (Mayo score-based clinical response); the primary comparison was clearly met in the favorable direction (18/32 vs 6/31, non-overlapping 95% CIs).

Reported efficacy

Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4) (met)

Result source: NCT01863771

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabgolimumab
Clinical remission (induction)10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
17.9% vs 6.4%+11.5 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 17.8% vs 6.4% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · secondary NCT00487539
Clinical remission (maintenance)20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
—Trial running · NCT03596645
Clinical response (induction)50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
54.9% vs 30.3%+24.6 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 51% vs 30.3% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · primary NCT00487539
Endoscopic improvement (induction)44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
—Trial running · NCT03596645
Corticosteroid-free remission (maintenance)13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
23.2% vs 18.4%+4.8 vs placebo100 mg · wk 54 · n 82NCT00488631
1 other result
  • 28.2% vs 18.4% 50 mg · wk 54 · n 78 · Phase 3 · secondary NCT00488631

Clinical remission (induction)

adalimumab
10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
golimumab
17.9% vs 6.4%+11.5 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 17.8% vs 6.4% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · secondary NCT00487539

Clinical remission (maintenance)

adalimumab
20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
golimumab
—Trial running · NCT03596645

Clinical response (induction)

adalimumab
50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
golimumab
54.9% vs 30.3%+24.6 vs placebo400 mg -> 200 mg · wk 6 · n 257NCT00487539
1 other result
  • 51% vs 30.3% 200 mg -> 100 mg · wk 6 · n 253 · Phase 2/3 · primary NCT00487539

Endoscopic improvement (induction)

adalimumab
44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
golimumab
—Trial running · NCT03596645

Corticosteroid-free remission (maintenance)

adalimumab
13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
golimumab
23.2% vs 18.4%+4.8 vs placebo100 mg · wk 54 · n 82NCT00488631
1 other result
  • 28.2% vs 18.4% 50 mg · wk 54 · n 78 · Phase 3 · secondary NCT00488631
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. adalimumab: 9 of 9 rows · golimumab: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
golimumab
Rows use multiple source trials
Clinical Remission
responder rate · % of participants
No placebo or comparator arm
100% (n=585) @ 388wk40 mg EOW/EWa,b,c
NCT00573794 · Phase 3 · monotherapy
36.6% (n=71) @ 12wkd,a,b,c
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
22.2% (n=72) @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Clinical Response
responder rate · % of participants
Maintenance
30.2% (n=248) vs 18.3% (n=246) placebo @ 52wk160/80/40e,f,g
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
6 other source trials
65.7% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
57.6% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
67.7% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
61.3% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
31.1% (n=90) vs 17.7% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
29.9% (n=87) vs 17.7% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
56.3% (n=32) vs 19.4% (n=31) placebo @ 54wk*e,f,g
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 18 participants as posted
2 other source trials
49.7% (n=151) vs 31.2% (n=154) placebo @ 54wk*100 mg
NCT00488631 · Phase 3 · combination · converted to % from 75 Participants as posted
47% (n=151) vs 31.2% (n=154) placebo @ 54wk*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 71 Participants as posted
Endoscopic Improvement
event count · % of participants
Induction
46.9% (n=130) vs 41.5% (n=130) placebo @ 8wk160/80/40d,h,i,j,k
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more dose
37.7% (n=130) vs 41.5% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.1% (n=257) vs 28.7% (n=251) placebo @ 6wk*400 mg -> 200 mgd,h,i,j,k
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 116 Participants as posted
show 1 more dose
42.3% (n=253) vs 28.7% (n=251) placebo @ 6wk*200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 107 Participants as posted
Partial Mayo
responder rate · % of participants
No placebo or comparator arm
44.1% (n=59) @ 288wk*l,b,f,m
NCT02632175 · Phase 3 · monotherapy · converted to % from 26 Participants as posted
24.9% (n=205) @ 54wkl,b,f,m
NCT02092285 · Phase 4 · registry result, not featured evidence
Sustained Clinical Remission
responder rate · % of participants
8.5% (n=248) vs 4.1% (n=246) placebo160/80/40b,f,n
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
27.8% (n=151) vs 15.6% (n=154) placebo*100 mgd,b,f,n
NCT00488631 · Phase 3 · combination · converted to % from 42 Participants as posted
show 3 more doses
38.9% (n=54) vs 24.1% (n=54) placebo*100 mg
NCT00488631 · Phase 3 · combination · converted to % from 21 Participants as posted
23.2% (n=151) vs 15.6% (n=154) placebo*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 35 Participants as posted
36.5% (n=52) vs 24.1% (n=54) placebo*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 19 Participants as posted
Dropout rate
6.9%160/80/40o
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
9.2%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
37.6%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
52.5%
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
10.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
56.4%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
34.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
23.8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—100 mgp
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 28 more results
—100 mg
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.6%Group1: Golimumab [Induction]
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—200 mg
NCT00488631 · Phase 3
29.2%100 mg
NCT00488631 · Phase 3 · combination
—100 mg - 200 mg
NCT00488631 · Phase 3
53.3%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg - 200 mg
NCT00488631 · Phase 3
—100 mg
NCT00488631 · Phase 3
44.8%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg
NCT00488631 · Phase 3
27.9%50 mg
NCT00488631 · Phase 3 · combination
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
1.2%400 mg -> 200 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
0.9%200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
4.2%100 mg -> 50 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
7.1%Golimumab Induction Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
4.3%Golimumab Maintenance Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
23.7%
NCT02318667 · Phase 4 · registry result, not featured evidence
17.1%
NCT02092285 · Phase 4 · registry result, not featured evidence
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
6.9%Combination Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Golimumab Monoth
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
3.1%160/80/40o
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
4.6%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
14.3%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5.6%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—100 mgp
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 28 more results
—100 mg
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
6.3%Group1: Golimumab [Induction]
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—200 mg
NCT00488631 · Phase 3
7.8%100 mg
NCT00488631 · Phase 3 · combination
—100 mg - 200 mg
NCT00488631 · Phase 3
12.3%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg - 200 mg
NCT00488631 · Phase 3
—100 mg
NCT00488631 · Phase 3
13%100 mg
NCT00488631 · Phase 3 · monotherapy
—100 mg
NCT00488631 · Phase 3
7.8%50 mg
NCT00488631 · Phase 3 · combination
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg - 100 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
—50 mg
NCT00488631 · Phase 3
0.3%400 mg -> 200 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
0.3%200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
2.8%100 mg -> 50 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
—Golimumab Induction Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
—Golimumab Maintenance Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
2.6%
NCT02318667 · Phase 4 · registry result, not featured evidence
3.4%
NCT02092285 · Phase 4 · registry result, not featured evidence
0%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
0%Combination Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Monotherapy Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
—Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
—Safety Follow-up: Golimumab Monoth
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Serious AEs
4%160/80/40o
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
3.8%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
12.1%Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.1%
NCT02632175 · Phase 3 · monotherapy
7.8%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
5.6%open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.6%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
13.9%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.2%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.8%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
5%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.6%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.8%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
9.9%Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.7%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
11.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
16.1%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.5%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
3.1%100 mgp
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 28 more results
10%100 mg
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
3.5%Group1: Golimumab [Induction]
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.3%200 mg
NCT00488631 · Phase 3
14.3%100 mg
NCT00488631 · Phase 3 · combination
7.1%100 mg - 200 mg
NCT00488631 · Phase 3
15.6%100 mg
NCT00488631 · Phase 3 · monotherapy
0%100 mg - 200 mg
NCT00488631 · Phase 3
19.4%100 mg
NCT00488631 · Phase 3
14.8%100 mg
NCT00488631 · Phase 3 · monotherapy
25%100 mg
NCT00488631 · Phase 3
8.4%50 mg
NCT00488631 · Phase 3 · combination
24%50 mg - 100 mg
NCT00488631 · Phase 3
5.3%50 mg - 100 mg
NCT00488631 · Phase 3
11.8%50 mg
NCT00488631 · Phase 3
0%50 mg
NCT00488631 · Phase 3
4.5%400 mg -> 200 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
3%200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
4.2%100 mg -> 50 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
9.5%Golimumab Induction Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
0%Golimumab Maintenance Therapy
NCT03124121 · Phase 4 · registry result, not featured evidence
10.5%
NCT02318667 · Phase 4 · registry result, not featured evidence
23.9%
NCT02092285 · Phase 4 · registry result, not featured evidence
1.4%Combination Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
1.4%Combination Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
4.2%Monotherapy Phase: Combination The
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
4.5%Monotherapy Phase: Golimumab Monot
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
0%Safety Follow-up: Combination Ther
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
0%Safety Follow-up: Golimumab Monoth
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
160/80/40o
colitis ulcerative 4% (placebo 3.6%)
fatigue 4% (placebo 2.2%)
headache 3.1% (placebo 7.2%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 17 more results
80/40
headache 6.9% (placebo 7.2%)
colitis ulcerative 5.4% (placebo 3.6%)
nasopharyngitis 4.6% (placebo 1.8%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
nasopharyngitis 17.5% (placebo 10.4%)
colitis ulcerative 16.3% (placebo 22.3%)
headache 8.6% (placebo 14.2%)
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 33.9%
upper respiratory tract infection 27.1%
nasopharyngitis 22%
NCT02632175 · Phase 3 · monotherapy
high dose
headache 9.8% (placebo 16.7%)
anaemia 5.9% (placebo 8.3%)
nausea 5.9% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
open-label high dose
headache 22.2% (placebo 16.7%)
abdominal pain 11.1% (placebo 8.3%)
oropharyngeal pain 11.1% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 12.5% (placebo 16.7%)
colitis ulcerative 6.3% (placebo 16.7%)
nasopharyngitis 6.3% (placebo 8.3%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
high dose
colitis ulcerative 11.1% (placebo 16.7%)
nasopharyngitis 11.1% (placebo 8.3%)
upper respiratory tract infection 11.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 18.2% (placebo 16.7%)
c-reactive protein increased 9.1% (placebo 0%)
colitis ulcerative 9.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 8.4%
nasopharyngitis 5.1%
arthralgia 3.1%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 6.1%
colitis ulcerative 5.3%
nasopharyngitis 4.2%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 13.4%
nasopharyngitis 13.1%
arthralgia 6.6%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 17.4%
nasopharyngitis 13.6%
arthralgia 6.7%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 15.2%
nasopharyngitis 7.3%
upper respiratory tract infection 6%
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
40 mg EOW/EW
colitis ulcerative 30.4%
viral upper respiratory tract infection 19.4%
arthralgia 10.5%
NCT00573794 · Phase 3 · monotherapy
160 mg/80 mg
nasopharyngitis 33.3% (placebo 21.9%)
iron deficiency anaemia 8.9% (placebo 7.3%)
headache 7.8% (placebo 6.3%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
80 mg/40 mg
nasopharyngitis 21.8% (placebo 21.9%)
injection site reaction 8% (placebo 2.1%)
dental caries 6.9% (placebo 5.2%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 13.2%
headache 13%
nasopharyngitis 8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
100 mgp
nasopharyngitis 53.1% (placebo 22.6%)
injection site erythema 15.6% (placebo 0%)
influenza 12.5% (placebo 3.2%)
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 26 more results
100 mg
nasopharyngitis 23.3% (placebo 22.6%)
colitis ulcerative 6.7% (placebo 6.5%)
upper respiratory tract inflammation 6.7% (placebo 0%)
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
nasopharyngitis 11.8% (placebo 22.6%)
colitis ulcerative 4.9% (placebo 6.5%)
injection site erythema 3.5% (placebo 0%)
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
200 mg
colitis ulcerative 28.6% (placebo 18.6%)
gastroenteritis viral 28.6% (placebo 0%)
nasopharyngitis 28.6% (placebo 6.4%)
NCT00488631 · Phase 3
100 mg
nasopharyngitis 14.9% (placebo 6.4%)
colitis ulcerative 11.7% (placebo 18.6%)
headache 7.8% (placebo 9%)
NCT00488631 · Phase 3 · combination
100 mg - 200 mg
nasopharyngitis 21.4% (placebo 6.4%)
headache 14.3% (placebo 9%)
viral upper respiratory tract infection 14.3% (placebo 0%)
NCT00488631 · Phase 3
100 mg
colitis ulcerative 12.1% (placebo 18.6%)
nasopharyngitis 8.1% (placebo 6.4%)
arthralgia 7.2% (placebo 7.1%)
NCT00488631 · Phase 3 · monotherapy
100 mg - 200 mg
colitis ulcerative 30% (placebo 18.6%)
diarrhoea 20% (placebo 4.5%)
gastroenteritis 20% (placebo 1.9%)
NCT00488631 · Phase 3
100 mg
colitis ulcerative 23.7% (placebo 18.6%)
nasopharyngitis 16.4% (placebo 6.4%)
sinusitis 9% (placebo 1.9%)
NCT00488631 · Phase 3
100 mg
colitis ulcerative 10.9% (placebo 18.6%)
headache 9.6% (placebo 9%)
nasopharyngitis 7.4% (placebo 6.4%)
NCT00488631 · Phase 3 · monotherapy
100 mg
colitis ulcerative 25% (placebo 18.6%)
nasopharyngitis 14.3% (placebo 6.4%)
arthralgia 10.7% (placebo 7.1%)
NCT00488631 · Phase 3
50 mg
colitis ulcerative 16.2% (placebo 18.6%)
nasopharyngitis 9.1% (placebo 6.4%)
headache 8.4% (placebo 9%)
NCT00488631 · Phase 3 · combination
50 mg - 100 mg
nasopharyngitis 16% (placebo 6.4%)
pyrexia 16% (placebo 4.5%)
upper respiratory tract infection 12% (placebo 2.6%)
NCT00488631 · Phase 3
50 mg - 100 mg
colitis ulcerative 10.5% (placebo 18.6%)
dyspepsia 10.5% (placebo 1.3%)
upper respiratory tract infection 10.5% (placebo 2.6%)
NCT00488631 · Phase 3
50 mg
colitis ulcerative 18.3% (placebo 18.6%)
nasopharyngitis 10.8% (placebo 6.4%)
arthralgia 9.7% (placebo 7.1%)
NCT00488631 · Phase 3
50 mg
abdominal pain 100% (placebo 2.6%)
abdominal pain upper 100% (placebo 0.6%)
bite 100% (placebo 0%)
NCT00488631 · Phase 3
400 mg -> 200 mg
headache 4.5% (placebo 5.2%)
nausea 3.6% (placebo 1.8%)
pyrexia 3% (placebo 2.1%)
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
200 mg -> 100 mg
nasopharyngitis 3.9% (placebo 3.6%)
headache 3.3% (placebo 5.2%)
anaemia 2.4% (placebo 1.8%)
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
100 mg -> 50 mg
headache 7% (placebo 5.2%)
injection site erythema 4.2% (placebo 0%)
anaemia 2.8% (placebo 1.8%)
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
colitis ulcerative 10.5%
NCT02318667 · Phase 4 · registry result, not featured evidence
colitis ulcerative 13.7%
nasopharyngitis 9.8%
colitis 7.3%
NCT02092285 · Phase 4 · registry result, not featured evidence
anaemia 5.6%
colitis ulcerative 5.6%
headache 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
colitis ulcerative 11.1%
anaemia 6.9%
upper respiratory tract infection 5.6%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
colitis ulcerative 8.5%
upper respiratory tract infection 8.5%
headache 4.2%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
colitis ulcerative 7.5%
anaemia 3%
headache 3%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
anaemia 0%
colitis ulcerative 0%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · combination
colitis ulcerative 5.2%
anaemia 0%
headache 0%
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cAssessment timepoints differ: 388 weeks versus 12 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation context differs: baseline_threshold differs (mayo<=12, mayo>=6 versus none recorded).
  6. fTreatment context has not been resolved for both arms.
  7. gAssessment timepoints differ: 52 weeks versus 54 weeks.
  8. hTrial phases differ: Phase 3 versus Phase 2/3.
  9. iPopulation context differs: prior_therapy differs (experienced versus naive).
  10. jTreatment context differs: monotherapy versus combination.
  11. kAssessment timepoints differ: 8 weeks versus 6 weeks.
  12. lTrial phases differ: Phase 3 versus Phase 4.
  13. mAssessment timepoints differ: 288 weeks versus 54 weeks.
  14. nThe assessment timepoint is not available for both results.
  15. oPopulation comparability has not been reviewed for 2 of these studies.
  16. pPopulation comparability has not been reviewed for 23 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Rectal Bleeding Subscore 0 1 77.7% (n=130) vs 66.2% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
70% (n=130) vs 66.2% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Physician Global Assessment Subscore 0 1 60% (n=130) vs 46.9% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
53.8% (n=130) vs 46.9% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Stool Frequency Subscore 0 1 48.5% (n=130) vs 37.7% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
36.2% (n=130) vs 37.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
IBDQ 42.2% (n=90) vs 39.6% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
48.3% (n=87) vs 39.6% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
60.8% (n=130) vs 57.7% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
53.8% (n=130) vs 57.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
58.1% (n=248) vs 45.5% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Remission 20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 14 more results
17.8% (n=90) vs 8.3% (n=96) placebo @ 32wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.2% (n=87) vs 8.3% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.3% (n=248) vs 8.5% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
29% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.2% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.3% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.5% (n=22) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
44% (n=25) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Clinical 23.8% (n=248) vs 12.2% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 44.4% (n=90) vs 30.2% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 2 more results
39.1% (n=87) vs 30.2% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
41.1% (n=248) vs 31.7% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 31.1% (n=90) vs 21.9% (n=96) placebo @ 32wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 8 more results
28.9% (n=90) vs 15.6% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.6% (n=87) vs 21.9% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
28.7% (n=87) vs 15.6% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
25% (n=248) vs 15.4% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
38.7% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
51.6% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
36.4% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
48.6% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Mucosal Healing 18.5% (n=248) vs 10.6% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
PGA 0-1 46% (n=248) vs 37.4% (n=246) placebo @ 8wk160/80/40
responder rate · % of participants
Induction
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Stool Frequency Subscore 0 1 40% (n=90) vs 32.3% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 2 more results
34.5% (n=87) vs 32.3% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
37.9% (n=248) vs 28.5% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Rectal Bleeding Subscore 0 1 71.1% (n=90) vs 67.7% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 2 more results
80.5% (n=87) vs 67.7% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
70.2% (n=248) vs 58.1% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

+ 43 further endpoints in the CSV export.

golimumab

Clinical Remission 50% (n=32) vs 6.5% (n=31) placebo
responder rate · % of participants
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 16 participants as posted
Mucosal Healing 42.4% (n=151) vs 26.6% (n=154) placebo100 mg
event count · % of participants
NCT00488631 · Phase 3 · combination · converted to % from 64 Participants as posted
show 2 more results
41.7% (n=151) vs 26.6% (n=154) placebo*50 mg
NCT00488631 · Phase 3 · combination · converted to % from 63 Participants as posted
59.4% (n=32) vs 16.1% (n=31) placebo*
NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 19 participants as posted
IBDQ 26.9 vs 14.8 placebo score @ 6wk400 mg -> 200 mg
absolute change · score
Induction
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
show 1 more result
27 vs 14.8 placebo score @ 6wk200 mg -> 100 mg
NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3
Clinical Response 61.1% (n=72) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy
show 1 more result
83.1% (n=71) @ 12wk
NCT03662542 · Phase 2 · registry result, not featured evidence · combination

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Rheumatoid Arthritismonoclonal antibody (fully human IgG1)
Reliable signal

NCT00195702 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).

Next expected readout: December 2027 · NCT06440629 (registry estimate)

Reported efficacy

Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24; Change From Baseline in Modified Total Sharp X-ray Score at Week 52 (Baseline and Week 52); Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52 (Baseline and Week 52): Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. (met)

Result source: NCT00195702

golimumab · Simponi

Marketed by Johnson & Johnson

Approved in Rheumatoid Arthritismonoclonal antibody (fully human IgG1)
Partial signal

NCT00264537 · Phase 3 · completed

This trial was well designed -- randomized, fully blinded, and placebo-controlled with over 600 patients -- but its two main outcomes told different stories: the joint-damage (structural) outcome clearly favored golimumab plus methotrexate, while the joint-response (ACR50) outcome for the combined golimumab groups narrowly missed statistical significance against placebo, with only one of the individual dose comparisons reaching significance on its own. A well-designed trial with a split result on its co-primary outcomes does not qualify as strong evidence of benefit.

Reported efficacy

ACR20 response at week 14; change from baseline in HAQ score at week 24: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant. (met)

Result source: NCT00264550

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabgolimumab
ACR2063.3% vs 29.5%+33.8 vs placebo40 mg every other week · wk 24 · n 207NCT00195702
28 other results
  • 50.3% vs 33.9% 40 mg every other week · wk 12 · n 159 · Phase 3 · primary NCT00647270
  • 57% vs 35% 40 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 47.3% vs 33.9% 80 mg monthly · wk 12 · n 205 · Phase 3 · primary NCT00647270
  • 51.2% vs 35% 80 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 60.8% vs 29.5% 20 mg weekly · wk 24 · n 212 · Phase 3 · primary NCT00195702
  • 58.9% vs 24% 40 mg every other week · wk 52 · n 207 · Phase 3 · secondary NCT00195702
  • 54.7% vs 24% 20 mg weekly · wk 52 · n 212 · Phase 3 · secondary NCT00195702
  • 75.4% vs 56.4% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 53.3% vs 61.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 68.7% vs 61.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 54.4% vs 62.6% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 72.8% vs 62.6% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 50% vs 59.9% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 69% vs 59.9% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 49.3% vs 56% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 69.4% vs 56% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 84.8% vs 80.4% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 66.4% vs 80.4% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
  • 68% vs 68% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 62% vs 68% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 64.1% vs 37.1% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 69.2% vs 57.1% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 66.7% vs 60% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 56.4% vs 68.6% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 51.3% vs 65.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 46.2% vs 65.7% wk 104 · n 39 · Phase 4 · secondary NCT01162421
44.4% vs 33.1%+11.3 vs placebo100 mg + placebo · wk 14 · n 133NCT00264550
25 other results
  • 36.5% vs 18% 100 mg · wk 14 · n 148 · Phase 3 · primary NCT00299546
  • 40.9% vs 15.9% 50 mg · wk 14 · n 132 · Phase 3 · primary NCT01248780
  • 34.7% vs 18% 50 mg · wk 14 · n 147 · Phase 3 · primary NCT00299546
  • 58.5% vs 24.9% 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · primary NCT00973479
  • 56.2% vs 33.1% 100 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 55.1% vs 33.1% 50 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 51.6% vs 49.4% 100 mg + placebo · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 35.3% vs 27.8% 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 42.6% vs 16% 100 mg · wk 24 · n 148 · Phase 3 · secondary NCT00299546
  • 42.4% vs 15.9% 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 31.3% vs 16% 50 mg · wk 24 · n 147 · Phase 3 · secondary NCT00299546
  • 48.1% vs 27.9% 4 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 39.8% vs 27.9% 2 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 61.6% vs 49.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% wk 24 · n 318 · Phase 3 · secondary NCT00264537
  • 59.6% vs 27.8% 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 59.6% vs 27.8% 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 51.6% vs 27.9% 4 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 55% vs 27.9% 2 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 55.9% vs 37.1% 100 mg every 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 79.4% vs 37.1% 100 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 60% vs 37.1% 50 mg every 4 weeks · wk 16 · n 35 · Phase 2 · primary NCT00207714
  • 50% vs 37.1% 50 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 62% vs 65.6% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896
ACR5041.2% vs 45.9%vs Methotrexatewk 52 · n 274NCT00195663
19 other results
  • 61.6% vs 45.9% wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 64.3% vs 38.7% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 35% vs 40.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 58.6% vs 40.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 41.6% vs 44.4% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 60.1% vs 44.4% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 36.9% vs 42.8% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 59% vs 42.8% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 78.1% vs 69.6% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 46.3% vs 69.6% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 48% vs 50% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 36% vs 40% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 43.6% vs 22.9% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 22.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 64.7% vs 51.6% wk 12 · n 17 · Phase 2 · secondary NCT03823391
  • 48.7% vs 40% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 34.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 45.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 33.3% vs 42.9% wk 104 · n 39 · Phase 4 · secondary NCT01162421
32.7% vs 29.4%+3.3 vs placebo100 mg + placebo · wk 24 · n 159NCT00264537
19 other results
  • 19.4% vs 13.2% 4 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 12.5% vs 13.2% 2 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 36.5% vs 29.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 40.3% vs 29.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 21.1% vs 13.2% 4 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 21.7% vs 13.2% 2 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 38.4% vs 29.4% wk 24 · n 318 · Phase 3 · primary NCT00264537
  • 18.2% vs 6.7% 100 mg · wk 14 · n 148 · Phase 3 · secondary NCT00299546
  • 15% vs 6.7% 50 mg · wk 14 · n 147 · Phase 3 · secondary NCT00299546
  • 34.9% vs 13.2% 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 28.9% vs 35.8% 100 mg + placebo · wk 24 · n 90 · Phase 3 · secondary NCT00264537
  • 11.6% vs 9.3% 4 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 8.6% vs 9.3% 2 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 44.6% vs 35.8% 100 mg + methotrexate · wk 24 · n 83 · Phase 3 · secondary NCT00264537
  • 44.2% vs 35.8% 50 mg + methotrexate · wk 24 · n 86 · Phase 3 · secondary NCT00264537
  • 25% vs 9.3% 4 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 18.6% vs 9.3% 2 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 44.4% vs 35.8% wk 24 · n 169 · Phase 3 · secondary NCT00264537
  • 34.8% vs 43.4% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896
ACR7047.4% vs 22.7%+24.7 vs placebowk 26 · n 171NCT00870467
16 other results
  • 28.1% vs 28.4% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 46.6% vs 28.4% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 28.8% vs 29.2% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 47.4% vs 29.2% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 25.9% vs 27.2% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 45.5% vs 27.2% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 19.7% vs 22.2% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 42.5% vs 22.2% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.5% vs 57.1% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 30.1% vs 57.1% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 23.1% vs 40% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 20% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 14.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 25.6% vs 22.9% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 8.6% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 15.4% vs 2.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
16.1% vs 25.9%vs Golimumab100 mg · wk 24.14 · n 70NCT01715896
DAS28-CRP remission38.5% vs 42.9%vs Standard of Carewk 104 · n 39NCT01162421
5 other results
  • 30.8% vs 34.3% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 22.9% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 31.4% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 11.4% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 17.9% vs 8.6% wk 13 · n 39 · Phase 4 · secondary NCT01162421
—Trial running · NCT03414502
HAQ-DI, change-0.6 vs -0.3−0.3 vs placebo40 mg every other week · wk 52 · n 204NCT00195702
22 other results
  • -0.6 vs -0.3 20 mg weekly · wk 52 · n 212 · Phase 3 · primary NCT00195702
  • -0.6 vs -0.2 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00195702
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.3 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.5 vs -0.3 40 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.3 80 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.6 vs -0.2 20 mg weekly · wk 24 · n 212 · Phase 3 · secondary NCT00195702
  • -0.8 vs -0.8 wk 52 · n 191 · Phase 3 · secondary NCT00195663
  • -1.1 vs -0.8 wk 52 · n 213 · Phase 3 · secondary NCT00195663
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
  • -0.5 vs -0.3 wk 26 · n 38 · Phase 4 · secondary NCT01162421
  • -0.4 vs -0.4 wk 13 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.5 wk 39 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 52 · n 38 · Phase 4 · secondary NCT01162421
  • -0.6 vs -0.6 wk 78 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 104 · n 38 · Phase 4 · secondary NCT01162421
0.1 vs 0.1±0 vs placebo100 mg + placebo · wk 24 · n 133NCT00264550
8 other results
  • 0.5 vs 0.1 100 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.3 vs 0.1 100 mg + placebo · wk 14 · n 133 · Phase 3 · secondary NCT00264550
  • -0.3 vs 0.2 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 0.5 vs 0.1 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · secondary NCT00973479
  • 0.4 vs 0.1 100 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • -0.4 vs -0.6 100 mg · wk 24.14 · n 70 · Phase 2 · secondary NCT01715896
Modified Sharp score, change0.1 vs 2.7−2.6 vs placebo40 mg every other week · wk 52 · n 183NCT00195702
15 other results
  • 0.8 vs 2.7 20 mg weekly · wk 52 · n 196 · Phase 3 · primary NCT00195702
  • 1.5 vs 2.4 wk 26 · n 148 · Phase 3 · primary NCT00870467
  • 3 vs 5.7 wk 52 · n 274 · Phase 3 · primary NCT00195663
  • 1.3 vs 5.7 wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 0.3 vs 1.3 40 mg every other week · wk 24 · n 183 · Phase 3 · secondary NCT00195702
  • 0.1 vs 4.8 40 mg every other week · wk 416 · n 81 · Phase 3 · secondary NCT00195702
  • 0.7 vs 6.2 40 mg every other week · wk 520 · n 79 · Phase 3 · secondary NCT00195702
  • 0.6 vs 1.3 20 mg weekly · wk 24 · n 196 · Phase 3 · secondary NCT00195702
  • 1.2 vs 4.8 20 mg weekly, then 40 mg every other week · wk 416 · n 70 · Phase 3 · secondary NCT00195702
  • 2.6 vs 6.2 20 mg weekly, then 40 mg every other week · wk 520 · n 70 · Phase 3 · secondary NCT00195702
  • 5.5 vs 10.4 wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 1.9 vs 10.4 wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 0.2 vs 1.6 wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 0.9 wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 2.2 wk 104 · n 39 · Phase 4 · secondary NCT01162421
1.3 vs 1.4−0.1 vs placebo100 mg + placebo · wk 52 · n 159NCT00264537
11 other results
  • 0.1 vs 1.4 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.7 vs 1.4 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.4 vs 1.4 wk 52 · n 318 · Phase 3 · primary NCT00264537
  • 2.2 vs 2.2 100 mg + placebo · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 0.2 vs 2.2 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 1.3 vs 2.2 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0.0 vs 1.1 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 0.7 vs 2.2 wk 52 · n 318 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 0 vs 0 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550

ACR20

adalimumab
63.3% vs 29.5%+33.8 vs placebo40 mg every other week · wk 24 · n 207NCT00195702
28 other results
  • 50.3% vs 33.9% 40 mg every other week · wk 12 · n 159 · Phase 3 · primary NCT00647270
  • 57% vs 35% 40 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 47.3% vs 33.9% 80 mg monthly · wk 12 · n 205 · Phase 3 · primary NCT00647270
  • 51.2% vs 35% 80 mg · wk 12 · n 121 · Phase 2/3 · primary NCT00538902
  • 60.8% vs 29.5% 20 mg weekly · wk 24 · n 212 · Phase 3 · primary NCT00195702
  • 58.9% vs 24% 40 mg every other week · wk 52 · n 207 · Phase 3 · secondary NCT00195702
  • 54.7% vs 24% 20 mg weekly · wk 52 · n 212 · Phase 3 · secondary NCT00195702
  • 75.4% vs 56.4% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 53.3% vs 61.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 68.7% vs 61.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 54.4% vs 62.6% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 72.8% vs 62.6% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 50% vs 59.9% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 69% vs 59.9% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 49.3% vs 56% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 69.4% vs 56% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 69.2% vs 71.4% wk 12 · n 454 · Phase 4 · primary NCT01500278
  • 84.8% vs 80.4% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 66.4% vs 80.4% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 64.5% vs 60.8% wk 6 · n 454 · Phase 4 · secondary NCT01500278
  • 68% vs 68% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 62% vs 68% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 64.1% vs 37.1% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 69.2% vs 57.1% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 66.7% vs 60% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 56.4% vs 68.6% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 51.3% vs 65.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 46.2% vs 65.7% wk 104 · n 39 · Phase 4 · secondary NCT01162421
golimumab
44.4% vs 33.1%+11.3 vs placebo100 mg + placebo · wk 14 · n 133NCT00264550
25 other results
  • 36.5% vs 18% 100 mg · wk 14 · n 148 · Phase 3 · primary NCT00299546
  • 40.9% vs 15.9% 50 mg · wk 14 · n 132 · Phase 3 · primary NCT01248780
  • 34.7% vs 18% 50 mg · wk 14 · n 147 · Phase 3 · primary NCT00299546
  • 58.5% vs 24.9% 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · primary NCT00973479
  • 56.2% vs 33.1% 100 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 55.1% vs 33.1% 50 mg + MTX · wk 14 · n 89 · Phase 3 · primary NCT00264550
  • 51.6% vs 49.4% 100 mg + placebo · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 35.3% vs 27.8% 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 42.6% vs 16% 100 mg · wk 24 · n 148 · Phase 3 · secondary NCT00299546
  • 42.4% vs 15.9% 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 31.3% vs 16% 50 mg · wk 24 · n 147 · Phase 3 · secondary NCT00299546
  • 48.1% vs 27.9% 4 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 39.8% vs 27.9% 2 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 61.6% vs 49.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · secondary NCT00264537
  • 61.6% vs 49.4% wk 24 · n 318 · Phase 3 · secondary NCT00264537
  • 59.6% vs 27.8% 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 59.6% vs 27.8% 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 51.6% vs 27.9% 4 mg/kg · wk 14 · n 128 · Phase 3 · secondary NCT00361335
  • 55% vs 27.9% 2 mg/kg · wk 14 · n 129 · Phase 3 · secondary NCT00361335
  • 55.9% vs 37.1% 100 mg every 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 79.4% vs 37.1% 100 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 60% vs 37.1% 50 mg every 4 weeks · wk 16 · n 35 · Phase 2 · primary NCT00207714
  • 50% vs 37.1% 50 mg every 2 or 4 weeks · wk 16 · n 34 · Phase 2 · primary NCT00207714
  • 62% vs 65.6% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896

ACR50

adalimumab
41.2% vs 45.9%vs Methotrexatewk 52 · n 274NCT00195663
19 other results
  • 61.6% vs 45.9% wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 64.3% vs 38.7% wk 26 · n 171 · Phase 3 · secondary NCT00870467
  • 35% vs 40.5% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 58.6% vs 40.5% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 41.6% vs 44.4% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 60.1% vs 44.4% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 36.9% vs 42.8% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 59% vs 42.8% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 78.1% vs 69.6% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 46.3% vs 69.6% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 48% vs 50% 40 mg every other week · wk 24 · n 50 · Phase 2 · secondary NCT01712178
  • 36% vs 40% 40 mg every other week · wk 12 · n 50 · Phase 2 · secondary NCT01712178
  • 43.6% vs 22.9% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 22.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
  • 64.7% vs 51.6% wk 12 · n 17 · Phase 2 · secondary NCT03823391
  • 48.7% vs 40% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 43.6% vs 34.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 38.5% vs 45.7% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 33.3% vs 42.9% wk 104 · n 39 · Phase 4 · secondary NCT01162421
golimumab
32.7% vs 29.4%+3.3 vs placebo100 mg + placebo · wk 24 · n 159NCT00264537
19 other results
  • 19.4% vs 13.2% 4 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 12.5% vs 13.2% 2 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 36.5% vs 29.4% 100 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 40.3% vs 29.4% 50 mg + methotrexate · wk 24 · n 159 · Phase 3 · primary NCT00264537
  • 21.1% vs 13.2% 4 mg/kg · wk 14 · n 128 · Phase 3 · primary NCT00361335
  • 21.7% vs 13.2% 2 mg/kg · wk 14 · n 129 · Phase 3 · primary NCT00361335
  • 38.4% vs 29.4% wk 24 · n 318 · Phase 3 · primary NCT00264537
  • 18.2% vs 6.7% 100 mg · wk 14 · n 148 · Phase 3 · secondary NCT00299546
  • 15% vs 6.7% 50 mg · wk 14 · n 147 · Phase 3 · secondary NCT00299546
  • 34.9% vs 13.2% 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 28.9% vs 35.8% 100 mg + placebo · wk 24 · n 90 · Phase 3 · secondary NCT00264537
  • 11.6% vs 9.3% 4 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 8.6% vs 9.3% 2 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 44.6% vs 35.8% 100 mg + methotrexate · wk 24 · n 83 · Phase 3 · secondary NCT00264537
  • 44.2% vs 35.8% 50 mg + methotrexate · wk 24 · n 86 · Phase 3 · secondary NCT00264537
  • 25% vs 9.3% 4 mg/kg · wk 24 · n 128 · Phase 3 · secondary NCT00361335
  • 18.6% vs 9.3% 2 mg/kg · wk 24 · n 129 · Phase 3 · secondary NCT00361335
  • 44.4% vs 35.8% wk 24 · n 169 · Phase 3 · secondary NCT00264537
  • 34.8% vs 43.4% 100 mg · wk 24.14 · n 70 · Phase 2 · primary NCT01715896

ACR70

adalimumab
47.4% vs 22.7%+24.7 vs placebowk 26 · n 171NCT00870467
16 other results
  • 28.1% vs 28.4% wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 46.6% vs 28.4% wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 28.8% vs 29.2% wk 76 · n 274 · Phase 3 · secondary NCT00195663
  • 47.4% vs 29.2% wk 76 · n 268 · Phase 3 · secondary NCT00195663
  • 25.9% vs 27.2% wk 52 · n 274 · Phase 3 · secondary NCT00195663
  • 45.5% vs 27.2% wk 52 · n 268 · Phase 3 · secondary NCT00195663
  • 19.7% vs 22.2% wk 26 · n 274 · Phase 3 · secondary NCT00195663
  • 42.5% vs 22.2% wk 26 · n 268 · Phase 3 · secondary NCT00195663
  • 69.5% vs 57.1% wk 78 · n 105 · Phase 4 · secondary NCT00420927
  • 30.1% vs 57.1% wk 78 · n 259 · Phase 4 · secondary NCT00420927
  • 23.1% vs 40% wk 104 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 20% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 30.8% vs 14.3% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 25.6% vs 22.9% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 8.6% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 15.4% vs 2.9% wk 13 · n 39 · Phase 4 · secondary NCT01162421
golimumab
16.1% vs 25.9%vs Golimumab100 mg · wk 24.14 · n 70NCT01715896

DAS28-CRP remission

adalimumab
38.5% vs 42.9%vs Standard of Carewk 104 · n 39NCT01162421
5 other results
  • 30.8% vs 34.3% wk 78 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 22.9% wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 28.2% vs 31.4% wk 39 · n 39 · Phase 4 · secondary NCT01162421
  • 35.9% vs 11.4% wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 17.9% vs 8.6% wk 13 · n 39 · Phase 4 · secondary NCT01162421
golimumab
—Trial running · NCT03414502

HAQ-DI, change

adalimumab
-0.6 vs -0.3−0.3 vs placebo40 mg every other week · wk 52 · n 204NCT00195702
22 other results
  • -0.6 vs -0.3 20 mg weekly · wk 52 · n 212 · Phase 3 · primary NCT00195702
  • -0.6 vs -0.2 40 mg every other week · wk 24 · n 204 · Phase 3 · secondary NCT00195702
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.3 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 40 mg every other week · wk 12 · n 159 · Phase 3 · secondary NCT00647270
  • -0.5 vs -0.3 40 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.1 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.2 vs 0 80 mg monthly · wk 12 · n 205 · Phase 3 · secondary NCT00647270
  • -0.4 vs -0.3 80 mg · wk 12 · n 120 · Phase 2/3 · secondary NCT00538902
  • -0.6 vs -0.2 20 mg weekly · wk 24 · n 212 · Phase 3 · secondary NCT00195702
  • -0.8 vs -0.8 wk 52 · n 191 · Phase 3 · secondary NCT00195663
  • -1.1 vs -0.8 wk 52 · n 213 · Phase 3 · secondary NCT00195663
  • -0.6 vs -0.7 wk 104 · n 454 · Phase 4 · secondary NCT01500278
  • -0.5 vs -0.3 wk 26 · n 38 · Phase 4 · secondary NCT01162421
  • -0.4 vs -0.4 wk 13 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.5 wk 39 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 52 · n 38 · Phase 4 · secondary NCT01162421
  • -0.6 vs -0.6 wk 78 · n 38 · Phase 4 · secondary NCT01162421
  • -0.5 vs -0.6 wk 104 · n 38 · Phase 4 · secondary NCT01162421
golimumab
0.1 vs 0.1±0 vs placebo100 mg + placebo · wk 24 · n 133NCT00264550
8 other results
  • 0.5 vs 0.1 100 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 24 · n 89 · Phase 3 · primary NCT00264550
  • 0.3 vs 0.1 100 mg + placebo · wk 14 · n 133 · Phase 3 · secondary NCT00264550
  • -0.3 vs 0.2 50 mg · wk 24 · n 132 · Phase 3 · secondary NCT01248780
  • 0.5 vs 0.1 2 mg/kg + MTX · wk 14 · n 395 · Phase 3 · secondary NCT00973479
  • 0.4 vs 0.1 100 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • 0.4 vs 0.1 50 mg + MTX · wk 14 · n 89 · Phase 3 · secondary NCT00264550
  • -0.4 vs -0.6 100 mg · wk 24.14 · n 70 · Phase 2 · secondary NCT01715896

Modified Sharp score, change

adalimumab
0.1 vs 2.7−2.6 vs placebo40 mg every other week · wk 52 · n 183NCT00195702
15 other results
  • 0.8 vs 2.7 20 mg weekly · wk 52 · n 196 · Phase 3 · primary NCT00195702
  • 1.5 vs 2.4 wk 26 · n 148 · Phase 3 · primary NCT00870467
  • 3 vs 5.7 wk 52 · n 274 · Phase 3 · primary NCT00195663
  • 1.3 vs 5.7 wk 52 · n 268 · Phase 3 · primary NCT00195663
  • 0.3 vs 1.3 40 mg every other week · wk 24 · n 183 · Phase 3 · secondary NCT00195702
  • 0.1 vs 4.8 40 mg every other week · wk 416 · n 81 · Phase 3 · secondary NCT00195702
  • 0.7 vs 6.2 40 mg every other week · wk 520 · n 79 · Phase 3 · secondary NCT00195702
  • 0.6 vs 1.3 20 mg weekly · wk 24 · n 196 · Phase 3 · secondary NCT00195702
  • 1.2 vs 4.8 20 mg weekly, then 40 mg every other week · wk 416 · n 70 · Phase 3 · secondary NCT00195702
  • 2.6 vs 6.2 20 mg weekly, then 40 mg every other week · wk 520 · n 70 · Phase 3 · secondary NCT00195702
  • 5.5 vs 10.4 wk 104 · n 274 · Phase 3 · secondary NCT00195663
  • 1.9 vs 10.4 wk 104 · n 268 · Phase 3 · secondary NCT00195663
  • 0.2 vs 1.6 wk 52 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 0.9 wk 26 · n 39 · Phase 4 · secondary NCT01162421
  • 0.0 vs 2.2 wk 104 · n 39 · Phase 4 · secondary NCT01162421
golimumab
1.3 vs 1.4−0.1 vs placebo100 mg + placebo · wk 52 · n 159NCT00264537
11 other results
  • 0.1 vs 1.4 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.7 vs 1.4 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · primary NCT00264537
  • 0.4 vs 1.4 wk 52 · n 318 · Phase 3 · primary NCT00264537
  • 2.2 vs 2.2 100 mg + placebo · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + placebo · wk 24 · n 133 · Phase 3 · secondary NCT00264550
  • 0.2 vs 2.2 100 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 1.3 vs 2.2 50 mg + methotrexate · wk 52 · n 159 · Phase 3 · secondary NCT00264537
  • 0.0 vs 1.1 2 mg/kg + MTX · wk 24 · n 395 · Phase 3 · secondary NCT00973479
  • 0.7 vs 2.2 wk 52 · n 318 · Phase 3 · secondary NCT00264537
  • 0 vs 0 100 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  • 0 vs 0 50 mg + MTX · wk 24 · n 89 · Phase 3 · secondary NCT00264550
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety

Coverage. adalimumab: 13 of 13 rows · golimumab: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Rows use multiple source trials
golimumab
Rows use multiple source trials
ACR20
responder rate · % of participants
No placebo or comparator arm
97% (n=133) @ 52wk*a,b,c
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 129 participants as posted
show 1 more dose
80% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 4 participants as posted
13.2% (n=91) @ 52wk50 mg SCa,b,c
NCT01004432 · Phase 3 · combination
show 1 more dose
9.2% (n=184) @ 52wk2 mg/kg IV
NCT01004432 · Phase 3 · combination
CDAI Clinical Remission
responder rate · % of participants
55.2% (n=105) vs 48.2% (n=112) placebo @ 78wk*a,d,b,c,e
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted
show 1 more dose
15.1% (n=259) vs 48.2% (n=112) placebo @ 78wk*
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted
5.7% (n=70) vs 17.6% (n=68) Golimumab @ 24.14wk100 mgd,b,c,e
NCT01715896 · Phase 2 · registry result, not featured evidence
DAS28-CRP
absolute change · score
-2.6 vs -2.6 Standard of Care score @ 104wkd,b,c,f
NCT01162421 · Phase 4 · registry result, not featured evidence
-2.11 vs -2.4 Golimumab score @ 24.14wk100 mgd,b,c,f
NCT01715896 · Phase 2 · registry result, not featured evidence
DAS28-ESR
absolute change · score
No placebo or comparator arm
-3.7 score @ 52wka,b,c,g
NCT00870467 · Phase 3 · registry result, not featured evidence
show 1 more dose
-1.9 score @ 52wk
NCT00870467 · Phase 3 · registry result, not featured evidence
0.209 score @ 76wk50 mg SCa,b,c,g
NCT01004432 · Phase 3 · combination
show 3 more doses
-0.136 score @ 76wk50 mg SC
NCT01004432 · Phase 3 · combination
-0.013 score @ 76wk50 mg SC
NCT01004432 · Phase 3 · combination
-0.017 score @ 76wk2 mg/kg IV
NCT01004432 · Phase 3 · combination
DAS28-ESR Remission
responder rate · % of participants
30.4% (n=171) vs 14.7% (n=163) placebo @ 26wk*h,b,c,i
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 52 participants as posted
17.3% (n=70) vs 19% (n=68) Golimumab @ 24.14wk100 mgh,b,c,i
NCT01715896 · Phase 2 · registry result, not featured evidence
EULAR Good, Moderate
responder rate · % of participants
63% (n=64) vs 63% (n=64) AbbVie Adalimumab @ 24wkb,c,j
NCT03172325 · Phase 3 · registry result, not featured evidence
81.3% (n=395) vs 40.1% (n=197) placebo @ 14wk2 mg/kg + MTXb,c,j
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
4 other source trials
69% (n=129) vs 44.2% (n=129) placebo @ 14wk*2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination · converted to % from 89 Participants as posted
62.5% (n=128) vs 44.2% (n=129) placebo @ 14wk*2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
73.4% (n=128) vs 44.2% (n=129) placebo @ 14wk*4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination · converted to % from 94 Participants as posted
64.3% (n=129) vs 44.2% (n=129) placebo @ 14wk*4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted
HAQ-DI
responder rate · % of participants
41% (n=39) vs 57.1% (n=35) Standard of Care @ 104wkd,b,c,f
NCT01162421 · Phase 4 · registry result, not featured evidence
2 other source trials
48.2% (n=274) vs 53.3% (n=257) Methotrexate @ 104wk*
NCT00195663 · Phase 3 · registry result, not featured evidence · converted to % from 132 participants as posted
63.8% (n=268) vs 53.3% (n=257) Methotrexate @ 104wk*
NCT00195663 · Phase 3 · registry result, not featured evidence · combination · converted to % from 171 participants as posted
58.7% (n=70) vs 69% (n=68) Golimumab @ 24.14wk100 mgd,b,c,f
NCT01715896 · Phase 2 · registry result, not featured evidence
HAQ-DI
absolute value · score
0.25 vs 0.19 AbbVie Adalimumab score @ 24wkb,c
NCT03172325 · Phase 3 · registry result, not featured evidence
1 other source trial
1.01 vs 0.97 Adalimumab score @ 24wk40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
0.25 vs 0 placebo score @ 24wk100 mga,b,c
NCT00299546 · Phase 3 · registry result, not featured evidence
show 1 more dose
0.125 vs 0 placebo score @ 24wk50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
SDAI Remission
responder rate · % of participants
52.4% (n=105) vs 45.5% (n=112) placebo @ 78wk*a,d,b,c,e
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 55 Participants as posted
show 1 more dose
15.1% (n=259) vs 45.5% (n=112) placebo @ 78wk*
NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted
7.2% (n=70) vs 18.9% (n=68) Golimumab @ 24.14wk100 mgd,b,c,e
NCT01715896 · Phase 2 · registry result, not featured evidence
Dropout rate
23.2%40 mg every other weekk
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
20.8%20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
—maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
—reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
24.8%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
66.7%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
32.5%
NCT01162421 · Phase 4 · registry result, not featured evidence
10.3%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
12.3%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
5.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
9.2%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
6.1%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
7%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
15.3%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
39.4%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
26.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
36%
NCT00690573 · Phase 3 · registry result, not featured evidence
9.4%DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
62.1%
NCT00195650 · Phase 3 · registry result, not featured evidence
5%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
8.2%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
11.2%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
22.7%40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
47.6%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
1.7%40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
4.1%80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
0%Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
2%40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
9.1%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
2.3%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
2%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
—Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
64%40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
36.5%100 mg + placebok
NCT00264537 · Phase 3
show 35 more results
—100 mg SC
NCT00264537 · Phase 3
—50 mg SC
NCT00264537 · Phase 3
37.7%100 mg + methotrexate
NCT00264537 · Phase 3 · combination
31.4%50 mg + methotrexate
NCT00264537 · Phase 3 · combination
30.8%100 mg + placebo
NCT00264550 · Phase 3
—100 mg SC injections
NCT00264550 · Phase 3
—50 mg SC injections
NCT00264550 · Phase 3
33.7%100 mg + MTX
NCT00264550 · Phase 3 · combination
19.1%50 mg + MTX
NCT00264550 · Phase 3 · combination
—50mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—2mg/kg IV
NCT01004432 · Phase 3 · combination
—2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
17.5%2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
11.4%50 mg
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
—100 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
56.2%100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
—50 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
60.1%50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
8.3%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—2 mg/kg intravenous + 50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
15.7%100 mg
NCT01715896 · Phase 2 · registry result, not featured evidence
23.5%100 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
14.7%100 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
20%50 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
29.4%50 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—40 mg every other weekk
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
—20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
—maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
—reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
1.3%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
—Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
—
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
—
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
12.5%
NCT01162421 · Phase 4 · registry result, not featured evidence
3.9%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
4.5%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
—ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
3.1%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
0%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
3.1%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
9.9%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
11.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
—
NCT00690573 · Phase 3 · registry result, not featured evidence
—DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
22.9%
NCT00195650 · Phase 3 · registry result, not featured evidence
3%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
4.4%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
3.4%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
—40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
11%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
1.7%40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
2.5%80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
—40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
0%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
2.3%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
2%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
—Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
—40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
20.1%100 mg + placebok
NCT00264537 · Phase 3
show 35 more results
—100 mg SC
NCT00264537 · Phase 3
—50 mg SC
NCT00264537 · Phase 3
21.4%100 mg + methotrexate
NCT00264537 · Phase 3 · combination
15.1%50 mg + methotrexate
NCT00264537 · Phase 3 · combination
13.5%100 mg + placebo
NCT00264550 · Phase 3
—100 mg SC injections
NCT00264550 · Phase 3
—50 mg SC injections
NCT00264550 · Phase 3
15.7%100 mg + MTX
NCT00264550 · Phase 3 · combination
10.1%50 mg + MTX
NCT00264550 · Phase 3 · combination
—50mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—50 mg SC
NCT01004432 · Phase 3 · combination
—2mg/kg IV
NCT01004432 · Phase 3 · combination
—2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
8.1%2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
5.3%50 mg
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
—100 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
17.6%100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
—50 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
14.4%50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
4.5%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
—2 mg/kg intravenous + 50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
—50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
—100 mg
NCT01715896 · Phase 2 · registry result, not featured evidence
8.8%100 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
2.9%100 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
5.7%50 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
11.8%50 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
Serious AEs
13%40 mg every other weekk
NCT00195702 · Phase 3
show 50 more results
—40 mg every other week
NCT00195702 · Phase 3
16%20 mg weekly
NCT00195702 · Phase 3
—20 mg weekly, then 40 mg every other week
NCT00195702 · Phase 3
7.4%maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
4.5%reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
2.7%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
7.7%40 mg Eow
NCT02198651 · Phase 4 · registry result, not featured evidence
1%Adalimumab Tapering
NCT02198651 · Phase 4 · registry result, not featured evidence
0%
NCT02451748 · Phase 4 · registry result, not featured evidence · combination
13%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
10.3%
NCT01162421 · Phase 4 · registry result, not featured evidence
7.1%high dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
3.9%low dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
11.4%ADA+MTX/ADA+MTX (Arm 2)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
6.9%ADA+MTX/OL ADA+MTX (Arm 3)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
7.1%20 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
3%10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2%5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
5.1%2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
23.7%Adalimumab
NCT00195663 · Phase 3 · registry result, not featured evidence
20.9%Adalimumab + Methotrexate
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
24%
NCT00690573 · Phase 3 · registry result, not featured evidence
4.1%DB Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
—DB Adalimumab/RE OL Adalimumab
NCT00870467 · Phase 3 · registry result, not featured evidence
51.1%
NCT00195650 · Phase 3 · registry result, not featured evidence
1%40 mg/0.8 mL
NCT01231321 · Phase 3 · registry result, not featured evidence
—40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
4.9%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
3.3%40 mg every other week
NCT00647270 · Phase 3 · registry result, not featured evidence
—80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
6.4%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
1.9%80 mg monthly
NCT00647270 · Phase 3 · registry result, not featured evidence
22.7%40 mg or 80 mg every other week
NCT00603993 · Phase 3 · registry result, not featured evidence
35.9%40 mg every other week
NCT00235872 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
0%40 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—80 mg
NCT00538902 · Phase 2/3 · registry result, not featured evidence
2.5%80 mg EOW
NCT00538902 · Phase 2/3 · registry result, not featured evidence
—Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
0%Period 1: Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
12.5%Period 2: Adalimumab / Adalimumab
NCT03823391 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02565810 · Phase 2 · registry result, not featured evidence
2.3%Current Formulation for 24 Weeks,
NCT01752855 · Phase 2 · registry result, not featured evidence
4.5%New Formulation for 48 Weeks
NCT01752855 · Phase 2 · registry result, not featured evidence
0%40 mg every other week
NCT01712178 · Phase 2 · registry result, not featured evidence
0%Current Formulation Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
0%New Formulation of Adalimumab
NCT01561313 · Phase 2 · registry result, not featured evidence
40%40 mg Eow
NCT00235833 · Phase 2 · registry result, not featured evidence
—100 mg + placebok
NCT00264537 · Phase 3
show 35 more results
38.7%100 mg SC
NCT00264537 · Phase 3
32%50 mg SC
NCT00264537 · Phase 3
—100 mg + methotrexate
NCT00264537 · Phase 3 · combination
—50 mg + methotrexate
NCT00264537 · Phase 3 · combination
—100 mg + placebo
NCT00264550 · Phase 3
45.7%100 mg SC injections
NCT00264550 · Phase 3
31.4%50 mg SC injections
NCT00264550 · Phase 3
—100 mg + MTX
NCT00264550 · Phase 3 · combination
—50 mg + MTX
NCT00264550 · Phase 3 · combination
4.4%50mg SC
NCT01004432 · Phase 3 · combination
2.7%50 mg SC
NCT01004432 · Phase 3 · combination
4.6%50 mg SC
NCT01004432 · Phase 3 · combination
4.7%50 mg SC
NCT01004432 · Phase 3 · combination
5.4%2mg/kg IV
NCT01004432 · Phase 3 · combination
19.7%2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
—2 mg/kg + MTX
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
6.1%50 mg
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
33.3%100 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
—100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
34.7%50 mg SC injections
NCT00299546 · Phase 3 · registry result, not featured evidence
—50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence
6%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
2.7%50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence
6.9%2 mg/kg intravenous + 50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
6.8%50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence
6.3%4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
13.3%2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence
9.1%50 mg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
14%4 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
13.7%2 mg/kg
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
2.9%100 mg
NCT01715896 · Phase 2 · registry result, not featured evidence
15.2%100 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
14.3%100 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
18.9%50 mg every 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
15.6%50 mg every 2 or 4 weeks
NCT00207714 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
40 mg every other weekk
injection site pain 17.9% (placebo 21.5%)
upper respiratory tract infection 16.9% (placebo 11%)
headache 11.6% (placebo 5%)
NCT00195702 · Phase 3
show 40 more results
20 mg weekly
injection site pain 17.5% (placebo 21.5%)
upper respiratory tract infection 16.5% (placebo 11%)
headache 13.2% (placebo 5%)
NCT00195702 · Phase 3
maximum tolerated dose
liver function test abnormal 8.8%
abdominal pain upper 2.9%
dry mouth 1.5%
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
reduced dose
dry mouth 3%
alanine aminotransferase increased 1.5%
cough 1.5%
NCT03505008 · Phase 4 · registry result, not featured evidence · combination
40 mg Eow
cough 2.7% (placebo 5%)
nasopharyngitis 2.7% (placebo 20%)
urinary tract infection 1.4% (placebo 0%)
NCT02198651 · Phase 4 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 10.3% (placebo 20%)
upper respiratory tract infection 7.7% (placebo 0%)
hepatic enzyme increased 5.1% (placebo 0%)
NCT02198651 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.7% (placebo 20%)
arthralgia 5.9% (placebo 0%)
influenza 4.9% (placebo 10%)
NCT02198651 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.3%
headache 10.7%
upper respiratory tract infection 10.3%
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis 25.6%
nasopharyngitis 20.5%
alanine aminotransferase increased 15.4%
NCT01162421 · Phase 4 · registry result, not featured evidence
high dose
nausea 10.3%
upper respiratory tract infection 7.7%
urinary tract infection 7.1%
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
low dose
nausea 9.7%
fatigue 9.1%
upper respiratory tract infection 9.1%
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
cough 6.7% (placebo 3.6%)
influenza 5.7% (placebo 2.7%)
nasopharyngitis 5.7% (placebo 3.6%)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 11.2% (placebo 6.3%)
nasopharyngitis 8.9% (placebo 3.6%)
alanine aminotransferase increased 6.2% (placebo 2.7%)
NCT00420927 · Phase 4 · registry result, not featured evidence · combination
injection site reaction 8.8%
headache 5.9%
nausea 5.9%
NCT03172325 · Phase 3 · registry result, not featured evidence
20 mg MTX
nasopharyngitis 11.2%
headache 9.2%
alopecia 8.2%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
10 mg MTX
nausea 13.1%
alopecia 6.1%
diarrhoea 6.1%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
5 mg MTX
diarrhoea 6%
headache 6%
nasopharyngitis 6%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
2.5 mg MTX
nausea 7.1%
arthralgia 6.1%
abdominal pain upper 4.1%
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 22.6%
headache 21.5%
nausea 17.5%
NCT00195663 · Phase 3 · registry result, not featured evidence
nasopharyngitis 30.2%
headache 20.5%
upper respiratory tract infection 18.7%
NCT00195663 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 56%
upper respiratory tract infection 56%
influenza 32%
NCT00690573 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.2% (placebo 16.6%)
hepatic function abnormal 8.2% (placebo 5.5%)
alanine aminotransferase increased 7.6% (placebo 3.7%)
NCT00870467 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 46.3%
rheumatoid arthritis 25.4%
sinusitis 24.9%
NCT00195650 · Phase 3 · registry result, not featured evidence
40 mg/0.8 mL
nasopharyngitis 4%
respiratory disorder 4%
headache 3%
NCT01231321 · Phase 3 · registry result, not featured evidence
40 mg every other week
nausea 5.5% (placebo 5.3%)
headache 4.9% (placebo 5.3%)
nasopharyngitis 4.9% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 6.6% (placebo 5.3%)
upper respiratory tract infection 2.6% (placebo 7%)
cough 0% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
80 mg monthly
upper respiratory tract infection 3.2% (placebo 7%)
nasopharyngitis 2.7% (placebo 5.3%)
cough 0% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
80 mg monthly
nausea 6.2% (placebo 5.3%)
upper respiratory tract infection 5.2% (placebo 7%)
headache 4.7% (placebo 5.3%)
NCT00647270 · Phase 3 · registry result, not featured evidence
40 mg or 80 mg every other week
nasopharyngitis 60.2%
adverse drug reaction 29.5%
antinuclear antibody positive 15.9%
NCT00603993 · Phase 3 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 45%
adverse drug reaction 23.6%
dna antibody positive 16.2%
NCT00235872 · Phase 3 · registry result, not featured evidence
40 mg EOW
upper respiratory tract infection 14% (placebo 11.7%)
injection site pruritus 5.8% (placebo 0%)
nasopharyngitis 5.8% (placebo 6.7%)
NCT00538902 · Phase 2/3 · registry result, not featured evidence
80 mg EOW
upper respiratory tract infection 12.4% (placebo 11.7%)
nasopharyngitis 7.4% (placebo 6.7%)
injection site pruritus 4.1% (placebo 0%)
NCT00538902 · Phase 2/3 · registry result, not featured evidence
urinary tract infection 11.8%
abdominal discomfort 5.9%
arthralgia 5.9%
NCT03823391 · Phase 2 · registry result, not featured evidence
nasopharyngitis 12.5%
bronchitis 6.3%
drug hypersensitivity 6.3%
NCT03823391 · Phase 2 · registry result, not featured evidence
40 mg
nasopharyngitis 8.2%
NCT02565810 · Phase 2 · registry result, not featured evidence
nasopharyngitis 15.9%
rheumatoid arthritis 9.1%
upper respiratory tract infection 9.1%
NCT01752855 · Phase 2 · registry result, not featured evidence
nasopharyngitis 13.6%
cystitis 9.1%
upper respiratory tract infection 9.1%
NCT01752855 · Phase 2 · registry result, not featured evidence
40 mg every other week
nasopharyngitis 10%
cystitis 8%
nausea 8%
NCT01712178 · Phase 2 · registry result, not featured evidence
pharyngitis 1.6%
rash erythematous 1.6%
protein urine present 0%
NCT01561313 · Phase 2 · registry result, not featured evidence
protein urine present 1.6%
pharyngitis 0%
rash erythematous 0%
NCT01561313 · Phase 2 · registry result, not featured evidence
40 mg Eow
nasopharyngitis 60%
diarrhoea 24%
pruritus 20%
NCT00235833 · Phase 2 · registry result, not featured evidence
100 mg SCk
upper respiratory tract infection 25.5%
nausea 22.6%
bronchitis 16.5%
NCT00264537 · Phase 3
show 26 more results
50 mg SC
upper respiratory tract infection 26.2%
alanine aminotransferase increased 18%
bronchitis 15.1%
NCT00264537 · Phase 3
100 mg SC injections
upper respiratory tract infection 34.8%
cough 19%
nasopharyngitis 19%
NCT00264550 · Phase 3
50 mg SC injections
upper respiratory tract infection 37.1%
cough 22.9%
bronchitis 17.1%
NCT00264550 · Phase 3
50mg SC
rheumatoid arthritis 9.9%
arthralgia 8.8%
bronchitis 6.6%
NCT01004432 · Phase 3 · combination
50 mg SC
upper respiratory tract infection 9.3%
depression 5.3%
sinusitis 5.3%
NCT01004432 · Phase 3 · combination
50 mg SC
upper respiratory tract infection 6.7%
headache 5.5%
urinary tract infection 5.5%
NCT01004432 · Phase 3 · combination
50 mg SC
upper respiratory tract infection 6.1%
urinary tract infection 6.1%
sinusitis 5.7%
NCT01004432 · Phase 3 · combination
2mg/kg IV
upper respiratory tract infection 8.2%
sinusitis 7.1%
bronchitis 6%
NCT01004432 · Phase 3 · combination
2 mg/kg + MTX
upper respiratory tract infection 13.7%
bronchitis 9.4%
rheumatoid arthritis 8.4%
NCT00973479 · Phase 3 · registry result, not featured evidence · combination
50 mg
upper respiratory tract infection 19.1%
liver function test abnormal 6.1%
anaemia 1.5%
NCT01248780 · Phase 3 · registry result, not featured evidence · combination
100 mg SC injections
upper respiratory tract infection 31.2%
nasopharyngitis 18.8%
rheumatoid arthritis 16.7%
NCT00299546 · Phase 3 · registry result, not featured evidence
50 mg SC injections
upper respiratory tract infection 25.5%
sinusitis 19.4%
headache 14.3%
NCT00299546 · Phase 3 · registry result, not featured evidence
50 mg subcutaneous
nasopharyngitis 0%
upper respiratory tract infection 0%
NCT00975130 · Phase 3 · registry result, not featured evidence
50 mg subcutaneous
nasopharyngitis 7.1%
upper respiratory tract infection 2.4%
NCT00975130 · Phase 3 · registry result, not featured evidence
2 mg/kg intravenous + 50 mg subcutaneous
upper respiratory tract infection 6.1%
nasopharyngitis 5.3%
NCT00975130 · Phase 3 · registry result, not featured evidence · combination
50 mg
upper respiratory tract infection 8.5% (placebo 9.3%)
nasopharyngitis 7.7% (placebo 5.4%)
rheumatoid arthritis 5.1% (placebo 4.7%)
NCT00361335 · Phase 3 · registry result, not featured evidence
4 mg/kg
upper respiratory tract infection 12.6% (placebo 9.3%)
rheumatoid arthritis 9.4% (placebo 4.7%)
bronchitis 6.3% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence
2 mg/kg
rheumatoid arthritis 15.6% (placebo 4.7%)
upper respiratory tract infection 10.9% (placebo 9.3%)
bronchitis 7.8% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence
50 mg
upper respiratory tract infection 7.2% (placebo 9.3%)
rheumatoid arthritis 6.9% (placebo 4.7%)
bronchitis 5.3% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
4 mg/kg
upper respiratory tract infection 12.2% (placebo 9.3%)
nausea 10.7% (placebo 7%)
bronchitis 7.7% (placebo 5.4%)
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
2 mg/kg
upper respiratory tract infection 12.1% (placebo 9.3%)
nausea 11% (placebo 7%)
headache 9.3% (placebo 10.1%)
NCT00361335 · Phase 3 · registry result, not featured evidence · combination
100 mg
nasopharyngitis 5.7%
headache 4.3%
hepatic enzyme increased 4.3%
NCT01715896 · Phase 2 · registry result, not featured evidence
100 mg every 4 weeks
headache 27.3% (placebo 20.6%)
nausea 21.2% (placebo 5.9%)
upper respiratory tract infection 15.2% (placebo 20.6%)
NCT00207714 · Phase 2 · registry result, not featured evidence
100 mg every 2 or 4 weeks
injection site erythema 28.6% (placebo 11.8%)
nasopharyngitis 22.9% (placebo 8.8%)
nausea 22.9% (placebo 5.9%)
NCT00207714 · Phase 2 · registry result, not featured evidence
50 mg every 4 weeks
headache 21.6% (placebo 20.6%)
nasopharyngitis 21.6% (placebo 8.8%)
rheumatoid arthritis 21.6% (placebo 14.7%)
NCT00207714 · Phase 2 · registry result, not featured evidence
50 mg every 2 or 4 weeks
nausea 25% (placebo 5.9%)
rheumatoid arthritis 21.9% (placebo 14.7%)
headache 18.8% (placebo 20.6%)
NCT00207714 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dTrial phases differ: Phase 4 versus Phase 2.
  5. eAssessment timepoints differ: 78 weeks versus 24.14 weeks.
  6. fAssessment timepoints differ: 104 weeks versus 24.14 weeks.
  7. gAssessment timepoints differ: 52 weeks versus 76 weeks.
  8. hTrial phases differ: Phase 3 versus Phase 2.
  9. iAssessment timepoints differ: 26 weeks versus 24.14 weeks.
  10. jAssessment timepoints differ: 24 weeks versus 14 weeks.
  11. kPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Sustained 8.7% (n=207) vs 1.5% (n=200) placebo40 mg every other week
responder rate · % of participants
NCT00195702 · Phase 3 · converted to % from 18 Participants as posted
show 1 more result
9.4% (n=212) vs 1.5% (n=200) placebo*20 mg weekly
NCT00195702 · Phase 3 · converted to % from 20 Participants as posted
Modified Sharp 0.09 vs 2.66 placebo score @ 52wk40 mg every other week
absolute change · score
Actual progression during study
NCT00195702 · Phase 3
show 1 more result
0.77 vs 2.66 placebo score @ 52wk20 mg weekly
Actual progression during study
NCT00195702 · Phase 3
SDAI Remission 29.6% (n=98) @ 26wk20 mg MTX
responder rate · % of participants
No placebo or comparator arm
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 7 more results
28.3% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
22% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
11.2% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
37.9% (n=66) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 25 Participants as posted
44.3% (n=61) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
39.7% (n=58) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 23 Participants as posted
44.3% (n=61) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
ACR50 62.2% (n=98) @ 26wk20 mg MTX
responder rate · % of participants
No placebo or comparator arm
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 15 more results
53.5% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
51% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
45.9% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
52.9% (n=68) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 36 Participants as posted
57.6% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 38 Participants as posted
29.8% (n=154) @ 24wklow dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
37.66% (n=155) @ 24wkhigh dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
88% (n=133) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 117 participants as posted
40% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 2 participants as posted
55.5% (n=238) @ 520wk*
NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 132 participants as posted
54.1% (n=516) @ 260wk*
NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 279 participants as posted
50% (n=44) @ 36wk
NCT01752855 · Phase 2 · registry result, not featured evidence
51.2% (n=44) @ 36wk
NCT01752855 · Phase 2 · registry result, not featured evidence
53.5% (n=44) @ 48wk
NCT01752855 · Phase 2 · registry result, not featured evidence
57.5% (n=44) @ 48wk
NCT01752855 · Phase 2 · registry result, not featured evidence
ACR70 45.9% (n=98) @ 26wk20 mg MTX
responder rate · % of participants
No placebo or comparator arm
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
show 11 more results
41.4% (n=99) @ 26wk10 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
34% (n=100) @ 26wk5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
24.5% (n=98) @ 26wk2.5 mg MTX
NCT01185301 · Phase 3 · registry result, not featured evidence · combination
32.4% (n=68) @ 48wk*maximum tolerated dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 22 Participants as posted
39.4% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 26 Participants as posted
13.25% (n=154) @ 24wklow dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
20.13% (n=155) @ 24wkhigh dose
NCT01185288 · Phase 4 · registry result, not featured evidence · combination
65.4% (n=133) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted
0% (n=5) @ 52wk*
NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 0 participants as posted
32.8% (n=238) @ 520wk*
NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 78 participants as posted
34.7% (n=516) @ 260wk*
NCT00195650 · Phase 3 · registry result, not featured evidence · converted to % from 179 participants as posted
HAQ-DI Less Than 0.5 58.8% (n=68) @ 48wkmaximum tolerated dose
event count · % of participants
No placebo or comparator arm
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 40 Participants as posted
show 1 more result
62.1% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
mTSS no Progression 66.2% (n=68) @ 48wkmaximum tolerated dose
event count · % of participants
No placebo or comparator arm
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 45 Participants as posted
show 1 more result
62.1% (n=66) @ 48wk*reduced dose
NCT03505008 · Phase 4 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted
Time to Flare NA vs NA placebo months
time to event · months
NCT02198651 · Phase 4 · registry result, not featured evidence
Disease Flare 36.3% (n=102) vs 45% (n=20) placebo
responder rate · % of participants
NCT02198651 · Phase 4 · registry result, not featured evidence
show 1 more result
15.4% (n=39) vs 8.6% (n=35) Standard of Care @ 104wk
NCT01162421 · Phase 4 · registry result, not featured evidence
Clinical Remission 10% (n=30) vs 12.5% (n=8) placebo @ 0wk
responder rate · % of participants
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 3 Participants as posted
show 3 more results
46.7% (n=30) vs 12.5% (n=8) placebo @ 4wk*
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 14 Participants as posted
56.7% (n=30) vs 37.5% (n=8) placebo @ 10wk*
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 17 Participants as posted
43.3% (n=30) vs 50% (n=8) placebo @ 16wk*
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to % from 13 Participants as posted
Time to Clinical Remission 1.41 vs 4.15 placebo months
time to event · months
NCT02198651 · Phase 4 · registry result, not featured evidence · converted to months from 6.1 weeks as posted
DAS28-ESR LDAS 35.5% (n=454) vs 33.5% (n=454) ADA+MTX @ 104wk
responder rate · % of participants
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
show 4 more results
45.6% (n=353) vs 42.4% (n=361) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
20.5% (n=454) vs 18.1% (n=454) ADA+MTX @ 6wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
30.4% (n=454) vs 29.7% (n=454) ADA+MTX @ 12wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination
47.7% (n=310) vs 46.6% (n=298) ADA+MTX @ 104wk
NCT01500278 · Phase 4 · registry result, not featured evidence · combination

+ 222 further endpoints in the CSV export.

golimumab

EULAR 63.2% (n=133) vs 50.4% (n=133) placebo @ 14wk100 mg + placebo
responder rate · % of participants
NCT00264550 · Phase 3 · converted to % from 84 Participants as posted
show 4 more results
58.8% (n=148) vs 29.3% (n=150) placebo @ 14wk*100 mg
NCT00299546 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted
55.8% (n=147) vs 29.3% (n=150) placebo @ 14wk*50 mg
NCT00299546 · Phase 3 · registry result, not featured evidence · converted to % from 82 participants as posted
75.3% (n=89) vs 50.4% (n=133) placebo @ 14wk*100 mg + MTX
NCT00264550 · Phase 3 · combination · converted to % from 67 Participants as posted
71.9% (n=89) vs 50.4% (n=133) placebo @ 14wk*50 mg + MTX
NCT00264550 · Phase 3 · combination · converted to % from 64 Participants as posted
EULAR 22.7% (n=75) @ 52wk50 mg SC
responder rate · % of participants
No placebo or comparator arm
NCT01004432 · Phase 3 · combination
show 6 more results
64.8% (n=3280) @ 8.67wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2127 Participants as posted
76.9% (n=3280) @ 17.33wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2522 Participants as posted
82.1% (n=3280) @ 26wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2692 Participants as posted
67% (n=3280) @ 8.67wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2199 Participants as posted
77.1% (n=3280) @ 17.33wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2530 Participants as posted
81.3% (n=3280) @ 26wk*50 mg subcutaneous
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2667 Participants as posted
ACR20 7.9% (n=63) @ 76wk50 mg SC
responder rate · % of participants
No placebo or comparator arm
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
show 3 more results
8.5% (n=47) @ 76wk50 mg SC
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
11.8% (n=212) @ 76wk50 mg SC
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
15.7% (n=102) @ 76wk2 mg/kg IV
ESR-based ACR 20 Response
NCT01004432 · Phase 3 · combination
EULAR Good, Moderate 82.1% (n=3280) @ 24wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 2692 Participants as posted
DAS28-ESR Remission 25.8% (n=248) @ 43.3wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Start of Month 11
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 64 Participants as posted
show 1 more result
24% (n=242) @ 43.3wk*2 mg/kg intravenous + 50 mg subcutaneous
Start of Month 11
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 58 Participants as posted
DAS28-ESR Remission 27% (n=248) @ 52wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
End of Month 12
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 67 Participants as posted
show 1 more result
24.4% (n=242) @ 52wk*2 mg/kg intravenous + 50 mg subcutaneous
End of Month 12
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 59 Participants as posted
DAS28-ESR Remission 7.7% (n=3280) @ 8.7wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Remission by DAS28-ESR - Month 2
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 251 Participants as posted
DAS28-ESR Remission 16.1% (n=3280) @ 17.3wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Remission by DAS28-ESR - Month 4
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 527 Participants as posted
DAS28-ESR Remission 23.9% (n=3280) @ 26wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Remission by DAS28-ESR - Month 6
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 784 Participants as posted
DAS28 (CRP) Remission 11.6% (n=3280) @ 8.7wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Remission by DAS28-CRP - Month 2
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 380 Participants as posted
DAS28 (CRP) Remission 23.3% (n=3280) @ 17.3wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Remission by DAS28-CRP - Month 4
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 765 Participants as posted
DAS28 (CRP) Remission 32.5% (n=3280) @ 26wk50 mg subcutaneous
responder rate · % of participants
No placebo or comparator arm
Remission by DAS28-CRP - Month 6
NCT00975130 · Phase 3 · registry result, not featured evidence · converted to % from 1065 Participants as posted

+ 24 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · golimumab's landscape